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Abstract
Dried blood spot (DBS) sampling for the purpose of therapeutic drug monitoring can be an
attractive alternative for conventional blood sampling, especially in children. This study
aimed to compare all costs involved in conventional sampling versus DBS home sampling in
two pediatric populations: renal transplant patients and hemato-oncology patients. Total
costs were computed from a societal perspective by adding up healthcare cost, patient
related costs and costs related to loss of productivity of the caregiver. Switching to DBS
home sampling was associated with a cost reduction of 43% for hemato-oncology patients
(€277 to €158) and 61% for nephrology patients (€259 to €102) from a societal perspective
(total costs) per blood draw. From a healthcare perspective, costs reduced with 7% for
hemato-oncology patients and with 21% for nephrology patients. Total savings depend on
the number of hospital visits that can be avoided by using home sampling instead of conven-
tional sampling.
Introduction
Therapeutic drug monitoring (TDM) is an important way to individualize drug dosing for a
variety of drug classes, such as anti-epileptics, antimicrobial agents (e.g. aminoglycosides and
glycopeptides, azole antifungal agents), antimetabolites (e.g. methotrexate) and immunosup-
pressants (e.g. cyclosporine, tacrolimus) [1–3]. The purpose of concentration guided dose
adaptation is to maintain drug exposure within predefined targets to ensure adequate efficacy
and to decrease the likelihood of adverse events [4]. Conventionally, drug concentrations are
measured in plasma, serum or whole blood obtained by venous sampling in a specialized
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healthcare facility [2, 3]. For patients treated on an outpatient basis, regular blood sampling
can be challenging. It is time consuming, as patients have to attend their hospital outpatient
clinic for blood sampling, and especially for children, frequent blood draws are associated with
patient burden. For example, after renal transplantation, we perform TDM of immunosup-
pressants weekly in the first month post-discharge based on local practice, as guidelines on the
frequency of TDM are lacking [5]. This frequency is slowly tapered to once every three months
but this tapering usually takes 6–9 months.
Dried blood spot (DBS) sampling could be a more convenient and less costly alternative to
conventional blood sampling. DBS sampling was first introduced for the screening of phenyl-
ketonuria in newborns (‘heel prick’ screening) in 1963 [6]. Especially over the last ten years,
the development of DBS assays for drug concentration measurements has increased consider-
ably [7, 8].
DBS sampling is used in different settings, from preclinical and clinical research including
large epidemiological studies to clinical settings [9–15]. The advantages of DBS sampling over
conventional venous sampling include the minimal invasive nature, the small amount of blood
required, the stability of the sample and the ease of self-sampling at home. Moreover, DBS
sampling allows for optimal sampling times (usual trough concentrations), which is often diffi-
cult to implement with outpatient visits. In addition, DBS sampling might potentially be cost-
saving as no healthcare professionals are involved in the sampling process. Although this
financial benefit of DBS sampling has been proposed in different clinical fields [16–18], no
thorough cost evaluation on DBS home sampling for TDM has been performed so far.
The objectives of this study were (1) to develop an analytical framework for an integral cost
evaluation of both conventional sampling and DBS home sampling; (2) to estimate and com-
pare all costs associated with the two sampling methods and; (3) to identify factors that influ-
ence total cost. The results are presented in a format suitable for input into further health
economic evaluations including cost-effectiveness analysis.
Methods
Setting
This cost evaluation is part of the PROTECT project funded by the Dutch Government, Ratio-
nal Pharmacotherapy program, grant 836021012 from The Netherlands Organisation for
Health Research and Development (ZonMW). PROTECT is coordinated by the Department
of Pharmacy of the Radboud university medical center in close collaborations with the Depart-
ments of Pediatric Nephrology and Pediatric Infectious Diseases and Immunology of the Rad-
boudumc Amalia Children’s Hospital, the Princess Ma´xima Center for oncology in Utrecht,
the Wilhelmina Children’s Hospital in Utrecht and the Department of Pharmacy of the Maas-
tricht University Medical Center.
Cases. Two pediatric patient populations, ‘cases’, were identified that are likely to benefit
from DBS home sampling: children treated with immunosuppressants (tacrolimus, mycophe-
nolic acid, cyclosporine) for the prevention of graft rejection after renal transplantation and
children with (risk of) invasive fungal infections treated with azole antifungal agents (vorico-
nazole, posaconazole, itraconazole). The main difference between these populations, relevant
for this cost-evaluation, is the travel time from home to the hospital. Only three hospitals per-
form renal transplantation in children in The Netherlands for which their travel distance is
expected to be higher than for pediatric hemato-oncology patients.
Framework for cost calculation. The literature was searched for articles to identify rele-
vant cost items to be incorporated in the framework for the cost evaluation (the search can be
Cost Evaluation of DBS Home Sampling
PLOS ONE | DOI:10.1371/journal.pone.0167433 December 12, 2016 2 / 17
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
found in S1 Text) and revealed no articles on the costs of DBS home sampling relevant for our
cases.
As a result the framework was designed without a prior format by evaluating the whole pro-
cess of blood sampling and TDM in patients treated on an outpatient basis. This included the
subsequent steps: the request of the analysis, travelling to the healthcare facility, the process of
blood sampling, analysis of the sample in the laboratory, interpretation of the results by the
pharmacist, and feed-back to the patient. DBS home sampling contained an additional step of
‘instruction of DBS sampling’ as patients performing DBS home sampling require an introduc-
tion with instruction from a specialized healthcare professional (e.g. a nurse).
Input from patient-organizations representing the specific patient populations, pediatri-
cians, hospital pharmacists, nurses, a hospital manager and a consultant hospital from “Con-
sultancy Group Process Improvement and Innovation”from the Radboud university center
was obtained to develop the framework for the two patient cases. Experts were asked to list
all resources used, from a societal perspective, so irrespective of who incurred the costs. The
time horizon was one single blood sample. This resulted in a list of resources used in the pro-
cess of conventional sampling and a list of resources used in the process of DBS home
sampling.
Resources used in each of the steps of the TDM process were subdivided into three catego-
ries, i.e. healthcare costs, patient costs and resources related to loss of productivity. Each cate-
gory consisted of different items representing invested time, material, or overhead. The final
framework was approved by the consulted experts. The sources of estimates for volume and
cost units and basic assumptions on the base-case can be found in S1 Table.
Analyses
Calculation sheet. The list of resources for both blood sampling methods was incorpo-
rated in a calculation sheet in Excel™ (Microsoft, USA). The calculation sheet contained all cost
units, the volume per unit, and the cost per unit.
Base-case analysis. Total costs for a single blood sample for the purpose of TDM were
computed by calculating all costs per cost unit (multiplying volume [e.g., minutes or parking
tickets] and cost per unit); and summing up over all categories of healthcare costs, patient
costs and resources related to loss of productivity; for both types of blood sampling: conven-
tional sampling and DBS home sampling; and for the two patient cases. Given the learning
effect in interpretation of the results after repeated analysis within the same patient, both
patient cases were considered as new patients in the base-case. The step ‘instruction of DBS
home sampling’ was not included in the integral costs of the DBS home sampling but was
reported separately. The number of occasions of DBS home sampling required to earn back
the costs of the instruction was also computed.
Sensitivity analyses. The following items were included in the sensitivity analysis: (1)
patient travel time; (2) travelling by public transport instead of by car; (3) time spend in the
hospital; (4) caregiver time valued as informal care; (5) caregiver time valued as loss of produc-
tivity for paid work; (6) sampling time; (7) costs of the laboratory analysis equals the formal
Dutch national tariff (College Tarieven Gezondheidszorg, CTG tariff) [19]; (8) time related to
review of the outcome of the sample analysis by the hospital pharmacist; (9) doctor’s time
related to feedback to the patient. Resources (1–4) were unique to conventional sampling
while resource (5) was unique to DBS home sampling. For details on the estimates used in the
sensitivity analyses see S2 Table.
Scenario analyses. Total costs for blood sampling for the purpose of TDM during disease
episode was calculated for each case for conventional sampling as well as for DBS sampling.
Cost Evaluation of DBS Home Sampling
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In pediatric nephrology, total costs on blood sampling for TDM of tacrolimus during the
first three months post discharge after pediatric transplantation was calculated. This time
period represents the most intense period in terms of outpatient visits with focus on blood
analysis. Total costs for both a stable and an instable patient was computed. It was assumed
that only instable patients may benefit from DBS homes sampling, as they require more inten-
sive blood sampling. Details on the frequency of sampling can be found in S3 Table. Only cost
associated with visits with the sole purpose of TDM were taken into account. In case visits
were combined with other blood draws or outpatient visits, general costs such as nurse’s time
or costs related to loss of productivity were not taken into account (best-case scenario). In case
additional sampling was required, such as in instable patients, all costs were taken into
account. For conventional sampling, these additional blood samples were assumed to be
drawn in a shared care center, assumed to be closer to a patient’s home [20].
In hemato-oncology, a treatment episode of invasive pulmonary aspergillosis (six months)
with voriconazole was used to calculate all costs related to blood sampling for the purpose of
TDM. Six months was considered representative based on literature [21] and our own experi-
ence in treating such infections in this population. A learning effect was taken into account for
interpretation of the result of the voriconazole concentration by the hospital pharmacist from
the third sample onwards, resulting in less time spent on interpretation and counseling (10 vs
20 minutes). This learning effect reflects the current situation in our hospital: interpretation
and counseling on azole antifungal TDM is performed by a selected number of hospital phar-
macists who know recurring patients. As hemato-oncology patients require regular blood sam-
pling for determination of biochemical parameters (liver function, electrolytes), only costs
associated with sampling for the purpose of voriconazole TDM were taken into account (best-
case scenario). In case extra sampling was required, such as in the first month of therapy for
dose individualization, all costs as included in the base-case were taken into account. Details
on the design of these two additional scenarios including frequency and location of sampling
are presented in S3 Table.
Results
Base case analysis
For children with renal transplants treated with immunosuppressants, total societal costs for
conventional sampling amount €259 for one sample while home sampling costs are €102 for a
sample (Tables 1 and 2). Total savings per sample are depicted in the last column, i.e. for a
nephrology patient, DBS home sampling results in €23 saving of patient costs, €107 saving of
costs related to loss of productivity and €27 saving of healthcare costs. Clearly, the difference is
mainly driven by a reduction in costs related to loss of productivity of the parent accompa-
nying his/her child to the hospital for the sampling process. The total societal costs of conven-
tional sampling in children treated with azole antifungal agents amount €277 while home
sampling amounts €158. Again, the difference between both methods is mainly associated
with a decrease in costs related to loss of productivity and less to patient costs and healthcare
costs. The difference in costs related to DBS sampling between the two patient cases lies mainly
in doctors/pharmacists time related to interpretation of the result and contacting the patient
(Tables 1 and 2).
Pie charts depicted in Fig 1 represent the distribution of patient costs, costs related to loss of
productivity and healthcare costs with conventional sampling and DBS home sampling for
both cases. While for conventional blood sampling healthcare costs represent 49–60% of total
costs, this is>97% with DBS home sampling. With home sampling, patient costs are absent
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and costs related to loss of productivity are reduced with>95% as compared to conventional
sampling.
The instruction of the patient and his/her parent by a specialized nurse is estimated to be
€163 for children with renal transplants and €139 for children treated with azole antifungal
Table 1. Base-case analysis for population (1): pediatric nephrology patients.
Cost unit Conventional sampling DBS home sampling Difference DBS—
Conventional
Volume/unit Cost/unit
(€)
Costs (€) Volume/unit Cost/unit
(€)
Costs (€) (€)
Request of the analysis
Healthcare costs
Doctor orders analysis 3.25 min 1.89 6.16 3.25 min 1.89 6.16 0
Overhead 44% 2.71 44% 2.71 0
Subtotal request of analysis 9 9 0
Blood drawing
Patient costs
Travel expenses car 104 km 0.19 19.88 NA -19.88
Travel expenses parking 1 ticket 3.02 3.02 NA -3.02
Costs related to loss of productivity
Travel time 145 min 0.58 84.37 NA -84.37
Time in hospital 45 min 0.58 26.22 NA -26.22
Home sampling NA 10 min 0.23 2.35 2.35
Send the sample by mail NA 6 min 0.23 1.41 1.41
Healthcare costs
Sampling by nurse 15 min 0.54 8.15 NA -8.15
Overhead 44% 3.58 NA -3.58
Sampling material 1 unit 6 6 1 unit 5.69 5.69 -0.31
Subtotal blood drawing 151 9 -142
Laboratory
Healthcare costs
Cost of laboratory analysis 1 unit 50.00 50.00 1 unit 50.00 50.00 0
Review by hospital pharmacist 5 min 1.89 9.47 3 min 1.89 5.68 -3.79
Overhead 44% 4.17 44% 2.50 -1.67
Subtotal laboratory 64 58 -6
Feedback to patient
Healthcare costs
Doctor processes result in medical
record
7 min 1.89 13.26 3.5 min 1.89 6.63 -6.63
Patient contacted 6 min 1.89 11.37 6 min 1.89 11.37 0
Overhead 44% 10.84 44% 7.92 -2.92
Subtotal feed-back to patient 35 26 -9
Total patient costs 23 0 -23
Total costs related to loss of
productivity
111 4 -107
Total healthcare costs 126 99 -27
Total societal costs 259 102 -157
Discrepancies between multiplications and sums may be due to rounding. DBS dried blood spot.
doi:10.1371/journal.pone.0167433.t001
Cost Evaluation of DBS Home Sampling
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agents, as shown in Table 3. The variation in costs is driven by differences in travel time. The
investment of the instruction of home sampling by the specialized nurse is almost completely
earned back at the second occasion of home sampling, both from a societal as from a health-
care perspective.
Table 2. Base-case analysis for population (2): pediatric hemato-oncology patients.
Cost unit Conventional sampling DBS home sampling DifferenceDBS—
Conventional
Volume/unit Cost/unit
(€)
Costs (€) Volume/unit Cost/unit
(€)
Costs (€) (€)
Request of the analysis
Healthcare costs
Doctor orders analysis 3.25 min 1.89 6.16 3.25 min 1.89 6.16 0
Overhead 44% 2.71 44% 2.71 0
Subtotal request 9 9 0
Blood drawing
Patient costs
Travel expenses distance 78 km 0.19 14.91 NA -14.91
Travel expenses parking 1 ticket 3.02 3.02 NA -3.02
Costs related to loss of productivity
Travel time 114 min 0.58 66.19 NA -67.59
Time in hospital 45 min 0.58 26.22 NA -26.22
Home sampling NA 10 min 0.23 2.35 2.33
Send the sample by mail NA 6 min 0.23 1.41 1.4
Healthcare costs
Sampling by nurse 15 min 0.54 8.15 NA -8.15
Overhead 44% 3.58 NA -3.58
Sampling material 1 unit 6 6 1 unit 5.69 5.69 -0.31
Subtotal blood drawing 128 9 -119
Laboratory
Healthcare costs
Cost laboratory analysis 1 unit 50.00 50.00 1 unit 50.00 50.00 0
Review by hospital pharmacist 20 min 1.89 37.89 20 min 1.89 37.89 0
Overhead 44% 16.67 44% 16.67 0
Subtotal laboratory 105 105 0
Feedback to patient
Healthcare costs
Doctor processes result in medical
record
7 min 1.89 13.26 7 min 1.89 13.26 0
Patient contacted 6 min 1.89 11.37 6 min 1.89 11.37 0
Overhead 44% 10.84 44% 10.84 0
Subtotal feedback to patient 35 35 0
Total patient costs 18 0 -18
Total costs related to loss of
productivity
92 4 -88
Total healthcare costs 167 155 -12
Total societal costs 277 158 -119
Discrepancies between multiplications and sums may be due to rounding. DBS dried blood spot.
doi:10.1371/journal.pone.0167433.t002
Cost Evaluation of DBS Home Sampling
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Sensitivity analysis
Tables 4 and 5 and tornado plots in Fig 2 show how total costs vary with pessimistic or oppor-
tunistic inputs. The main factor of influence is the time of the hospital pharmacist and doctor
related with review of the outcome of the sample analysis and feedback to the patient, respec-
tively. For example, if the time of feedback to the patient increased from 6 minutes (base case)
to 20 minutes, total costs of conventional blood drawing increased with 15% from €259 to
€297 for children with immunosuppressant therapy. The costs of sample analysis in the labora-
tory are also influential. If the prize doubled to €100 total costs increased with 18–19% for con-
ventional sampling and with about 32–49% for DBS home sampling. The time for a nurse to
take a sample showed to be less influential on total costs, doubling the sampling time from 15
to 30 minutes led to about 4–5% increase in total costs.
Fig 1. Pie chart of costs in euro’s (€) ordered by perspective. DBS dried blood spot.
doi:10.1371/journal.pone.0167433.g001
Cost Evaluation of DBS Home Sampling
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Valuing all caregiver time as informal care in the situation of conventional sampling in a
healthcare facility, decreased total costs with 20–25%. When all caregiver time was valued as
loss of productivity instead of informal care in the situation of DBS home sampling, this was
associated with a 4–6% increase in total cost.
Scenario analyses
Total costs associated with blood sampling for the purpose of TDM of tacrolimus in the pediat-
ric nephrology patient in the first three months post discharge after renal transplantation
amount to €756 for a stable patient conventionally sampled. This is based on a total of 7 sam-
ples (see S3 Table). As all samples for tacrolimus TDM are supposed to be drawn together with
routine sample taking, DBS home sampling does not play a role in regular patient care and
hence does not impact costs in a stable transplant patient. For the instable transplant patient, a
total of 11 samples will be drawn which results in a total cost of €1401 for blood sampling for
the purpose of TDM. DBS home sampling can reduce this total cost to €1226 in case three
samples are taken at home. These three samples were based on consultation with two pediatric
nephrologists.
Total costs for TDM of voriconazole in a hemato-oncology patient amount to €3972 based
on a total of 28 samples taken conventionally during a disease episode of 6 months. DBS home
sampling can reduce total costs to €3553 in case four samples are taken at home.
Discussion
This is the first study evaluating the costs of conventional blood sampling in a healthcare facil-
ity and comparing this to DBS home sampling for the purpose of TDM. Costs for a single
blood sample as well as costs for a complete disease episode were estimated in two populations.
Table 3. Resources on instruction of home sampling for both populations.
Nephrology Hemato-oncology Difference between populations Nephrology—
Hemato-oncology
Instruction of DBS finger
prick
Volume
(unit)
Cost/unit
(€)
Costs
(€)
Volume
(unit)
Cost/unit
(€)
Costs
(€)
(€)
Patient costs
Travel expenses car 104 km 0.19 19.88 78 km 0.19 14.91 4.97
Travel expenses parking 1 ticket 3.02 3.02 1 ticket 3.02 3.02 0
subtotal 23 18 5
Costs related to loss of
productivity
Travel time 145 min 0.58 84.37 114 min 0.58 66.19 18.18
Time in hospital 45 min 0.58 26.22 45 min 0.58 26.22 0
subtotal 111 92 19
Healthcare costs
Time of nurse for
instruction
30 min 0.54 16.29 30 min 0.54 16.29 0
Overhead 44% 7.17 44% 7.17 0
Instruction material 1 unit 5.69 5.69 1 unit 5.69 5.69 0
subtotal 29 29 0
Total 163 139 24
Discrepancies between multiplications and sums may be due to rounding. DBS dried blood spot.
doi:10.1371/journal.pone.0167433.t003
Cost Evaluation of DBS Home Sampling
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Table 4. Sensitivity analysis population (1): pediatric nephrology patients.
Conventional sampling Costs of the
item (€)
Total
cost (€)
Difference with
base case (€)
DBS home sampling Costs of the
item (€)
Total
cost (€)
Difference with
base case (€)
Resources regarding loss
of productivity
Travel time patient
Base case 84 259 NA NA
Optimistic scenario 1st
quartile
52 227 -32 NA
Pessimistic scenario 3rd
quartile
128 303 43 NA
Productivity loss time in
hospital
Base case (45 min) 26 259 NA NA
Optimistic scenario (25
min)
15 248 -12 NA
Pessimistic scenario (75
min)
44 277 17 NA
Caregiver time is valued
as informal care
Caregiver time is valued
as loss of paid work
Base case: valued as loss
of paid work
111 259 NA Base case: valued as
informal care
4 102 NA
Caregiver time valued as
informal care
45 193 -66 Caregiver time valued as
loss of paid work
9 108 6
Patient costs
Patient travels by public
transport
Base case: car 23 259 NA NA
Public transport 40 276 17 NA
NA
Healthcare costs
Sampling time nurse Sampling time caregiver
Base case (15 min) 12 259 NA Base case (sampling takes
10 min)
2 102 NA
Optimistic scenario
(sample takes 10 min)
8 255 -4 Optimistic scenario (5 min) 1 101 -1
Pessimistic scenario
(sample takes 30 min)
23 271 12 Pessimistic scenario (20
min)
5 105 2
Costs of the lab analysis Costs of the lab analysis
Base case 50 259 NA Base case 50 102 NA
CTG tariff 31 241 -19 CTG tariff 31 84 -19
Twice base case 100 309 50 Twice base case 100 152 50
Costs related to review
by pharmacist
Costs related to review
by pharmacist
Base case (5 min) 14 259 NA Base case (3 min) 8 102 NA
Optimistic scenario (2.5
min)
7 252 -7 Optimistic scenario (2 min) 5 100 -3
Pessimistic scenario (10
min)
27 273 14 Pessimistic scenario (10
min)
27 121 19
Time related to
contacting patient
Time related to
contacting patient
Base case (total 6 min) 16 259 NA Base case (total 6 min) 16 102 NA
Optimistic scenario (total 3
min)
8 251 -8 Optimistic scenario (total 3
min)
8 94 -8
(Continued )
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From a societal perspective, total costs for a single blood draw with DBS home sampling were
substantially lower compared to conventional blood sampling in a healthcare facility, i.e., 2.5
fold lower for nephrology patients and 1.8 fold lower for hemato-oncology patient. Total costs
associated with conventional sampling for the purpose of TDM in the first three or six months
post transplantation and in hemato-oncology patients with an invasive fungal infection respec-
tively, could be reduced 1.1 fold.
Factors influencing total costs per blood draw were the time of the pharmacist and physi-
cian, the costs of sample analysis, and the valuation of caregiver time (informal care of lost pro-
ductivity from paid labour). The scenario analyses per disease episode showed that the saving
as a result of DBS largely depends on the proportion of hospital visits that can be avoided.
Cost reductions are dependent on how many outpatient visits can be avoided, as children
may travel to the hospital not only for drug concentration measurement but also for sampling
of biochemical parameters and/or for an outpatient visit with their physician. This largely
depends on the population and the clinical status of individual patient within this population.
Implementation of DBS home sampling requires alertness and flexibility of the treating physi-
cian and the healthcare system in order to decide when best to apply home sampling and when
not. Especially upon titration of the drug, home sampling can substitute outpatient visits. Cur-
rently, hemato-oncology patients treated from an outpatient basis have weekly appointments
with their hemato-oncologist. For each additional sample required for monitoring of blood
concentrations, patients require to travel to our center for blood sampling as local general hos-
pitals have no facilities in assessment of azole blood concentrations. Clearly, DBS home sam-
pling can reduce costs for every additional sample. Those savings are mainly true from a
societal point-of-view as they mostly cover savings in loss of productivity and loss of patient
(travel) costs.
As it stands, no thorough cost evaluation regarding DBS home sampling for TDM has been
published. DBS sampling was only hypothesized to be cost-saving as compared to conven-
tional sampling [17, 18]. One study evaluated the costs of different sampling methods for the
assessment of prenatal alcohol exposure and concluded that DBS sampling from the newborn
was cheaper as compared to conventional venous sampling of the mother or meconium analy-
sis. DBS sampling was cost-saving in terms of personnel involved in venous sampling and
shipping costs when compared to venous sampling of the mother [16]. DBS sampling resulted
in a reduction in nurse’s time of 11 minutes, comparable to our 15 minutes time reduction.
Our results confirm that DBS home sampling is cost-saving.
The calculated costs and figures are inevitably associated with uncertainty. Sensitivity analy-
ses identified several items that specifically influenced total costs. The costs of the laboratory
analysis of the sample depend on several local factors including equipment, cost prices of the
laboratory, number of samples per run and number of runs per year. It is assumed that no spe-
cific analytical equipment is required for the analysis of DBS samples as mostly liquid chroma-
tography mass-spectrometry is used for the analysis of both plasma and DBS samples[8]. For
the base-case scenario a general price of €50 was used. The sensitivity analyses showed that
Table 4. (Continued)
Conventional sampling Costs of the
item (€)
Total
cost (€)
Difference with
base case (€)
DBS home sampling Costs of the
item (€)
Total
cost (€)
Difference with
base case (€)
Pessimistic scenario (20
min)
54 297 38 Pessimistic scenario (20
min)
54 141 38
Discrepancies between multiplications and sums may be due to rounding. DBS dried blood spot.
doi:10.1371/journal.pone.0167433.t004
Cost Evaluation of DBS Home Sampling
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Table 5. Sensitivity analysis population (2): pediatric oncology patients.
Conventional sampling Costs of the
item (€)
Total
cost (€)
Difference with
base case (€)
DBS home sampling Costs of the
item (€)
Total
cost (€)
Difference with
base case (€)
Resources regarding loss
of productivity
Travel time patient
Base case 66 277 NA NA
Optimistic scenario 1st
quartile
36 247 -30 NA
Pessimistic scenario 3rd
quartile
91 302 25 NA
Productivity loss time in
hospital
Base case (45 min) 26 277 NA NA
Optimistic scenario (25
min)
15 265 -12 NA
Pessimistic scenario (75
min)
44 294 17 NA
Patient costs
Patient travels by public
transport
Base case: car 18 277 NA NA
Public transport 30 289 12 NA
NA
Caregiver time is valued
as informal care
Caregiver time is valued
as loss of paid work
Base case: valued as loss
of paid work
92 277 NA Base case: valued as
informal care
4 158 NA
Caregiver time valued as
informal care
37 222 -55 Caregiver time valued as
loss of paid work
9 164 6
Healthcare costs
Sampling time nurse Sampling time caregiver
Base case (15 min) 12 277 NA Base case 2 158 NA
Optimistic scenario
(sample takes 10 min)
8 273 -4 Optimistic scenario (5 min) 1 157 -1
Pessimistic scenario
(sample takes 30 min)
23 289 12 Pessimistic scenario (20
min)
5 161 2
Costs of the lab analysis Costs of the lab analysis
Base case 50 277 NA Base case 50 158 NA
CTG tariff 27 254 -23 CTG tariff 27 135 -23
Twice base case 100 327 50 Twice base case 100 208 50
Costs related to review
by pharmacist
Costs related to review
by pharmacist
Base case (20 min) 55 277 NA Base case 55 158 NA
Optimistic scenario (5 min) 14 236 -41 Optimistic scenario (5 min) 14 117 -41
Pessimistic scenario (40
min)
109 331 54 Pessimistic scenario (40
min)
109 213 54
Time related to
contacting patient
Time related to
contacting patient
Base case (6 min) 16 277 NA Base case (6 min) 16 158 NA
Optimistic scenario (3 min) 8 269 -8 Optimistic scenario (total 3
min)
8 150 -8
(Continued )
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total costs decreased substantially by using a national maximal tariff (CTG tariff) [19] that
applies for the analysis of outsourced samples in The Netherlands. Inversely, doubling the
price to €100 also impacted total costs considerably. National tariffs do not always cover all
costs involved with measurement of the sample, especially for drugs that are infrequently mea-
sured such as azole antifungal agents. A €100 fee probably better reflects the real costs involved
in sample measurement. The current analysis did not take into account investments required
for developing a DBS method, which may be more costly than plasma method development.
On the other hand, several approaches have been made to speed-up the analytical method
such as automated flow-through desorption or reduced sample pre-treatment resulting in a
cost-effective analytical method[22, 23]. These technical innovations will further reduce analy-
sis costs in the future.
Another item especially influencing total cost was the time spend by the physician and hos-
pital pharmacist for the interpretation of the result of the analysis and feed-back to the patient
respectively, which is explained by the relatively high salary costs of these healthcare profes-
sionals. Although this finding has no clinical consequences and is equally true for both con-
ventional sampling as DBS home sampling, it can be a good starting point for strategies to
further decrease costs associated with blood sampling (e.g. efficient administration processes,
good clinical handover).
As home sampling has not been implemented yet, assumptions were made on the time
required for parents to sample their child. Total costs were only marginally influenced by time
spent by the parent on sampling, as shown by the sensitivity analysis. Of note, these cost were
indeed influenced by how this caregiver time was valued, i.e. as loss of productivity for paid
work or as informal care. The majority of total cost involved in DBS home sampling included
healthcare costs.
Implementing a DBS home sampling method will on one hand lead to cost savings from a
societal and patient perspective, as patients have less travel costs and reduced loss of productiv-
ity. Societal costs will decline and social health security may benefit from reduced healthcare
costs. It may on the other hand lead to a loss of income for a healthcare facility. It is difficult to
predict how this latter aspect will impact hospital related costs. This will become more clear
when DBS sampling becomes more common practice. Our analysis and results are valid for
the social and economical situation in the Netherlands. Probably similar trends can be
expected upon extrapolation to other countries with similar health-care systems but this is
only hypothetical.
Adequate sampling times are very important for good interpretation of the exposure to
immunosuppressants and azoles: preferably trough concentrations (before a next dose of the
drug) are measured [24]. With conventional sampling during an outpatient visit it is difficult
to ‘capture’ this time point as patients usually take their medication in the (early) morning
before the outpatient visit. With home sampling this trough concentration can be ‘captured’
facilitating the interpretation by the treating physician and hospital pharmacist. DBS home
sampling is expected to result in better samples in terms of sampling moments, to increase the
Table 5. (Continued)
Conventional sampling Costs of the
item (€)
Total
cost (€)
Difference with
base case (€)
DBS home sampling Costs of the
item (€)
Total
cost (€)
Difference with
base case (€)
Pessimistic scenario (20
min)
54 315 38 Pessimistic scenario (20
min)
54 196 38
Discrepancies between multiplications and sums may be due to rounding. DBS dried blood spot.
doi:10.1371/journal.pone.0167433.t005
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Fig 2. One-way sensitivity analysis of the impact of the variation of different items on total societal cost as compared to the base-case. DBS
dried blood spot.
doi:10.1371/journal.pone.0167433.g002
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interpretability of the outcome and to facilitate subsequent decision making on dose adapta-
tions. Other advantages of DBS sampling are not easily represented in costs, such as the mini-
mal volume required or the less invasive nature of sampling.
DBS home sampling may reduce costs even more when biochemical parameters such as
renal function parameters for nephrology patients or liver function tests in case of treatment
with azole antifungal agents are measured along with drug concentrations. Those parameters
are important to take into account in further studies. At this moment, most biochemical
parameters require a plasma or serum sample to be taken at the hospital. DBS assays for creati-
nine have been published but some are associated with issues of precision [25, 26]. Combining
home sampling for the purpose of TDM with assessment of disease specific parameters will
probably result in increased benefit for the patient as more outpatient visits may be avoided.
This will most likely also lead to lower societal costs. Clearly, DBS home sampling has a great
potential for implementation in regular patient care and this can be further improved by com-
bining measurement of different components in one sample. When implementing a DBS
home sampling method for quantitative analysis of compounds, careful instruction with regu-
lar feed-back on the spot quality and thorough screening of the spot before processing the sam-
ple in the laboratory is important. Improperly collected samples may impact quality of care as
the analytical outcome may be modified resulting in improper clinical decision. Moreover,
improperly collected samples may negatively impact costs.
We would like to stress that DBS sampling is a nice alternative in case patients travel to the
hospital only for blood sampling and do not have an appointment with their physician or (spe-
cialized) nurse practitioner. It is obvious that home sampling should not replace doctor’s
appointments.
Based on the current cost evaluation, DBS home sampling can be considered cost-saving.
Whether DBS home sampling is more efficient, depends on the accuracy and precision of the
DBS assay compared to the conventional (plasma) assay [27–30]. Alongside our clinical study
on efficacy of DBS sampling, a cost-effectiveness of DBS home sampling is performed. Also
patient preferences and the experience regarding DBS home sampling are subject of study. We
anticipate that children would prefer a finger prick over regular sampling and that parents
would be ready to perform finger prick sampling of their child. Literature shows that DBS
home sampling in a clinical study among female adult cancer patients was successful with
about 70% participation [18]. Another study on islet autoantibody screening in patients aged
12–38 years showed that patients would prefer DBS home sampling if this would avoid visits
to the clinic, despite that DBS finger prick sampling was more painful [12].
Conclusion
This study is the first evaluation comparing the costs involved in regular blood sampling with
the costs involved in DBS home sampling for the purpose of TDM. From societal perspective,
total costs per blood draw decrease drastically with home sampling. Patient costs are reduced
to zero and cost related to loss of productivity are decreased with >95%. Scenario analyses
revealed that total cost savings depends heavily on how many visits can be avoided. Based on
the results of this study we can conclude that DBS home sampling is associated with a reduc-
tion in costs both from a healthcare as from a societal perspective, but the size of the reduction
differs considerably per individual patient in a population.
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